Skip to main content
SpringerLink
Log in

Clinical trials report

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cannon CP, Braunwald E, McCabe CH, et al.: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  2. Grundy SM, Cleeman JI, Bairey NB, et al.: Implications of recent clinical trials for National Cholesterol Education Program ATP III. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  3. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7–22.

    Article  Google Scholar 

  4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

  5. Pearson TA, Mensah GA, Smith HY, et al.: Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. Circulation 2003, 107:499–511.

    Article  PubMed  Google Scholar 

  6. Ridker PA, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959–1965.

    Article  PubMed  CAS  Google Scholar 

  7. Nissen SE, Tuzco EM, Schoenhagen P, et al.: Statin therapy, LDL-C, C-reactive protein and coronary artery disease. N Engl J Med 2005, 352:29–38.

    Article  PubMed  CAS  Google Scholar 

  8. Ridker PA, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004, 109:1955–1959.

    Article  PubMed  Google Scholar 

  9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005–2016.

  11. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  12. Sever PS, Dalhof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA); a multicenter randomized trial. Lancet 2003, 361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  13. ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002, 288:2998–3007.

    Article  Google Scholar 

  14. Sangiorgi G, Ramberger JA, Severson A, et al.: Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 1998, 31:126–133.

    Article  PubMed  CAS  Google Scholar 

  15. Kondos GT, Hoff JA, Sevrukov A, et al.: Electron beam tomography coronary artery calcium and cardiac events: a 37 month follow-up of 5635 initially asymptomatic low to intermediate risk adults. Circulation 2003, 107:2571–2576.

    Article  PubMed  Google Scholar 

  16. Callister TQ, Raggi P, Cooil R, et al.: Effect of HMG-CoA reductase inhibition on coronary artery disease as assessed by electron beam computed tomography. N Engl J Med 1998, 339:1972–1978.

    Article  PubMed  CAS  Google Scholar 

  17. Budoff MJ, Bakhsheshi H, Mao S, et al.: Rates of progression of coronary calcium by electron beam tomography. Am J Cardiology 2000, 86:8–11.

    Article  CAS  Google Scholar 

  18. Hecht HS, Harmon SM: Relation of aggressiveness of lipid lowering treatment to changes of calcified plaque burden by electron beam tomography. Am J Cardiol 2003, 92:334–336.

    Article  PubMed  Google Scholar 

  19. Raggi P, Shaw LJ, Berman DS, et al.: Gender based differences in prognostic value of coronary lcification. J Women Health 2004, 13:273–283.

    Article  Google Scholar 

  20. Raggi P, Callister TQ, Shaw LJ: Progression of coronary artery calcium and risk of first MI in patients receiving cholesterol lowering therapy. Arterioscler Thromb Vasc Biol 2004, 24:1272–1277.

    Article  PubMed  CAS  Google Scholar 

  21. Taylor AJ, Kent SM, Flaherty PJ, et al.: Arterial biology for the investigation of the treatment effects reducing cholesterol: a randomized trial comparing the effects of atrovastatin and pravastatin on carotid intima media thickness. Circulation 2002, 106:2055–2060. of

    Article  PubMed  CAS  Google Scholar 

  22. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared to moderate lipid lowering therapy on progression of coronary atherosclerosis. JAMA 2004, 291:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  23. O’Keefe JH, Cordain L, Harris WH, et al.: Optimal low density lipoprotein is 50 to 70 mg/dl. J Am Coll Cardiol 2004, 43:2142–2146.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michael Clearfield DO
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clearfield, M. Clinical trials report. Curr Atheroscler Rep 8, 7–12 (2006). https://doi.org/10.1007/s11883-006-0058-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-006-0058-0

Keywords

Search

Navigation